Clinical Trials Highlights

Bladder Cancer Kidney Cancer Phase III randomized “Adjuvant study of MK-3475 A Phase 3 RandOmized Study Comparing PERioperative (pembrolizumab) in muscle invasive and locally Advanced Nivolumab Vs. Observation in Patients with Renal Cell urothelial carcinoma” (AMBASSADOR) versus observation Carcinoma Undergoing Nephrectomy (PROSPER RCC) Principal investigator: Petros Grivas, MD, PhD Principal investigator: Sarah Psutka, MD Reference number: NCT03244384 Reference number: NCT03055013 Blood and Marrow Transplantation Lymphoma Multi-center Phase II Randomized Controlled Trial of Naïve A Phase II, Open-label, Single-arm, Multicohort, Multicenter T Cell Depletion for Prevention of Chronic Graft-Versus- Trial to Evaluate the Efficacy and Safety of Jcar017 in Adult Host Disease in Children and Young Adults Subjects with Relapsed or Refractory Indolent B-cell Non- Principal investigator: Marie E. Bleakley, MD, PhD, MMSC hodgkin Lymphoma (NHL) Reference number: NCT03779854 Principal investigator: David G. Maloney, MD, PhD Reference number: NCT04245839 Breast Cancer A Pilot Study to Estimate the Safety and Tolerability of the A Phase 2, Open-label Study Of Intratumoral Tavokinogene Combination of Polatuzumab Vedotin with Dose Adjusted Telseplasmid Plus Electroporation in Combination with Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin Intravenous Pembrolizumab Therapy in Patients with (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Inoperable Locally Advanced or Metastatic Triple Negative Non-Hodgkin Lymphomas Breast Cancer Principal investigator: Ryan C. Lynch, MD Principal investigator: Shaveta Vinayak, MD, MS Reference number: NCT04231877 Reference number: NCT03567720 An Open-Label, Phase I/II Study of JCAR017 in Subjects with Esophageal Cancer Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma A Phase 2 Study of Apx005m in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Principal investigator: David G. Maloney, MD, PhD Resectable Esophageal and Gastroesophageal Junction Reference number: NCT03331198 Cancers. Immune Response to COVID-19 Vaccines in Patients with Principal investigator: Veena Shankaran, MD, MS CLL/SLL Reference number: NCT03165994 Principal investigator: Chaitra S. Ujjani, MD Head and Neck Cancer Reference number: NCT04852822 Durvalumab (MEDI4736), Tremelimumab and Palliative Melanoma Hypofractionated Image Guided Radiation Therapy (HIGRT) A Phase 2, Multicenter Study of Autologous Tumor in Patients with Recurrent/Metastatic Squamous Cell Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Carcinomas of the Head and Neck Previously Treated with Patients with Solid Tumors Immune Checkpoint Inhibitors Principal investigator: Sylvia M. Lee, MD Principal investigator: Cristina P. Rodriguez, MD Reference number: NCT03645928 Reference number: NCT03522584 Multiple Myeloma Neuro-oncology A Randomized Study of Daratumumab Plus Lenalidomide Study of Vorasidenib (AG-881) in Participants with Residual Versus Lenalidomide Alone as Maintenance Treatment in or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation Patients with Newly Diagnosed Multiple Myeloma Who (INDIGO) Are Minimal Residual Disease Positive After Frontline Principal investigator: Tresa McGranahan, MD Autologous Stem Cell Transplant Reference number: NCT04164901 Principal investigator: Andrew J. Cowan, MD Reference number: NCT03901963 Prostate Cancer Myeloid CART-PSMA-TGFßRDN-02 A Phase 1 Open-Label, Multi- Center Study of PSMA Targeted Genetically Modified A Phase IIb, Open-Label, Single Arm, Multi-Center Study to Chimeric Antigen Receptor T Cells in Patients with Assess the Efficacy and Safety of BST-236 as a Single Agent Metastatic Castration Resistant Prostate Cancer in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Principal investigator: Michael Schweizer, MD Not Eligible for Standard Induction Therapy Reference number: NCT04227275 Principal investigator: Mary-Beth M. Percival, MD Reference number: NCT03435848 Sarcoma A Phase I/II Study Evaluating Escalating Doses of 211at- A Phase 1/2 Study Of Abi-009 (Nab-rapamycin) with labeled anti-cd45 Mab Bc8-b10 (211at-bc8-b10) followed Pazopanib (Votrient®) in Patients with Advanced by Related Haplo-identical Allogeneic Hematopoietic Nonadipocytic Soft-tissue Sarcomas Cell Transplantation for High-risk Acute Leukemia or Principal investigator: Lee D. Cranmer, MD, PhD, FACP Myelodysplastic Syndrome (MDS) Reference number: NCT03660930 Principal investigator: Phoung T. Vo, MD Reference number: NCT03670966 Thoracic Cancer A Phase I/II Study of ALX148 in Combination With Personalized Radiation Therapy through Functional Lung Azacitidine in Patients With Higher Risk Myelodysplastic Avoidance and Response-Adaptive Dose Escalation: Utilizing Syndrome (MDS) (ASPEN-02) Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT) Principal investigator: Bart L. Scott, MD Principal investigator: Jing Zeng, MD Reference number: NCT04417517 Reference number: NCT02773238 Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm Principal investigator: Roland B. Walter, MD, PhD, MS Reference number: NCT04195945

Find out more about Seattle Cancer Care Alliance’s clinical trials: seattlecca.org/research/clinical-trials